Subject(s)
Aortic Coarctation/diagnosis , Aortic Rupture/diagnosis , Diverticulum/diagnosis , Mitral Valve/pathology , Adult , Aortic Coarctation/complications , Aortic Coarctation/surgery , Aortic Rupture/complications , Aortic Rupture/surgery , Diverticulum/complications , Diverticulum/surgery , Humans , Male , Mitral Valve/surgeryABSTRACT
BACKGROUND AND AIMS: Long-term competence of any aortic prosthesis is critical to its clinical durability. Bioprosthetic valves, and in particular the stentless type have been proposed to offer superior haemodynamic profiles with consequent potential for superior left-ventricular mass regression. These benefits however are balanced by the potential longevity of the implanted valve. The aims of this study were to assess medium-term Toronto aortic valve function and its effect on left-ventricular function. METHODS: Between 1992 and 1996 86 patients underwent Toronto aortic valve replacement for aortic valve disease and were followed up annually. Prospectively collected data was analyzed for all patients where detailed echocardiographic follow-up was available. Echocardiographic studies were analyzed at 2+/-0.6 and 6+/-1.4 years after valve replacement. Data collected included left-ventricular systolic and diastolic dimensions, fractional shortening and left-ventricular mass. In addition, data on aortic valve and root morphology, peak aortic velocities, time velocity integral, stroke volume and the mechanism of valve failure where relevant, were also collected. RESULTS: Complete echocardiographic data were available for eighty-four patients, age 69+/-9 years, 62 male. Additional coronary artery bypass grafting was performed in 38% of patients. Twelve (14%) valves had failed during follow-up, 7 (8%) requiring re-operation. Valve failure was associated with morphologically bicuspid native aortic valve (9/12), and progressive dilatation of the aortic sinuses, sino-tubular junction and ascending aorta (11/12). Left-ventricular mass index remained high (184+/-75 g/m(2)) and did not continue to regress between early and medium-term follow-up (175.8+/-77 g/m(2)). CONCLUSIONS: Although more than 90% of implanted Toronto aortic valves remained haemodynamically stable with low gradient at medium-term follow-up, young age and larger aortic dimensions in patients with valve failure suggest better outcome if used in the elderly with normal aortic root geometry.
Subject(s)
Aortic Valve/surgery , Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation , Ventricular Function, Left , Aged , Aortic Valve/diagnostic imaging , Aortic Valve/pathology , Disease Progression , Female , Heart Valve Diseases/diagnostic imaging , Heart Valve Diseases/pathology , Hemodynamics , Humans , Male , Prospective Studies , Time Factors , Treatment Outcome , UltrasonographySubject(s)
Cardiopulmonary Bypass/methods , Heart Failure/diagnostic imaging , Heart Failure/surgery , Intra-Aortic Balloon Pumping/methods , Aged , Cohort Studies , Combined Modality Therapy , Echocardiography, Transesophageal , Elective Surgical Procedures , Female , Follow-Up Studies , Heart Failure/mortality , Heart-Assist Devices , Humans , Male , Middle Aged , Risk Assessment , Severity of Illness Index , Survival Rate , Treatment OutcomeABSTRACT
Stentless glutaraldehyde-preserved bioprosthetic valves for the aortic position were introduced into clinical practice in 1988. Their introduction coincided with the publication of several long-term observational studies of aortic homografts, which showed superior freedom from structural valve damage compared to the first generation stented porcine bioprosthesis. There followed 10 years of intensive investigation into the haemodynamic characteristics of stentless valves. These studies have demonstrated superior haemodynamic features in terms of transvalvular pressure gradients, effective orifice area, and more complete regression of left ventricular hypertrophy. Despite these advantages, stentless valves have yet to be adopted widely. This review seeks to explain this paradox.
Subject(s)
Aortic Valve Stenosis/surgery , Bioprosthesis , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation , Hemodynamics , Humans , Hypertrophy, Left Ventricular/physiopathology , Prosthesis Design , Risk Assessment , Treatment Outcome , Ventricular Function, LeftABSTRACT
BACKGROUND: A lifetime mechanical solution for advanced heart failure must be reliable, with a low risk of life-threatening complications. After extensive laboratory testing, we began clinical trials with an axial flow pump for long-term treatment of New York Heart Association class IV, transplant-ineligible patients. METHODS AND RESULTS: The Jarvik 2000 is a continuous flow device that is implanted in the apex of the left ventricle with offloading to the descending thoracic aorta. Skull-based percutaneous power delivery was derived from cochlear implant technology. We used this system in 4 patients with end-stage dilated cardiomyopathy. Exercise capacity, quality of life, device parameters, and native heart function were monitored serially. One patient died from right heart failure at 3 months. The other patients were discharged from hospital between 3 and 8 weeks postoperatively and are currently New York Heart Association I or II. Follow-up lasted between 9 and 20 months. There has been no device failure or hemolysis. Native heart function and quality of life were markedly improved. CONCLUSIONS: The Jarvik 2000 is a true assist (rather than replacement) device that functions synergistically with the native left ventricle and provides excellent quality of life. Adverse events are infrequent. This blood pump may provide a mechanical solution for end-stage heart failure in the community.
